Stocks to Watch: ARNA, VVUS, OREX & More

Take a look at some of Wednesday's midday movers:

Arena Pharmaceuticals soared after its obesity drug was approved by the FDA. Rivals Vivus and Orexigen also moved higher as they have their own obesity drugs in review.

Weight Watchers , meanwhile, fell following the news.

Chipotle shares were slammed after an ITG report said revenues and same store sales would be weaker than expected in the second quarter. Panera Bread was down in sympathy.

» Read More

Department stores, including Macy’s, Nordstrom and Saks, all moved lower after Citigroup lowered their ratings, citing concerns that high end consumer spending may slow in the second half of the year.

Barclays reversed earlier morning losses after news it will pay more than $400 million to settle charges that it tried to manipulate the Libor, which sets key global interest rates.

Monsanto moved higher after it posted higher than expected earnings as net revenue jumped 17 percent. This on sales gains in seeds and herbicides.

Entropic was also higher after the company, which provides connectivity chips to TV-Service providers, said it expects second quarter results to come in stronger than it previously estimated.

Omeros slid after the biopharma company said it plans to offer an undisclosed amount of shares to help fund its development of two medical products for eye and knee surgeries.

Autozone and Advance Auto Parts both skid in sympathy with O’Reilly Auto, which warned of weaker sales in June.

Merck was higher after it said it will record sales and profits for two more years from AstraZeneca’s reflux drugs Nexium and Prilosec.

Homebuilders rose, including DR Horton, KB Homes, Pulte and Toll Brothers after Lennar reported its second quarter profit rose as deliveries and new orders increased.

Westport Innovations jumped after it said it signed a second deal with General Motors to develop natural gas engine technology for light-duty vehicles.

Questions? Comments? Email us at marketinsider@cnbc.com